FDA approvals for new indications of existing drugs can significantly impact a pharmaceutical company's market potential and stock price. This approval expands the use of Fanapt®, potentially increasing its market share and revenue. Given the importance of such regulatory milestones in the pharmaceutical industry, this news is likely to be viewed positively by investors, potentially leading to a short-term increase in VNDA's stock price.